Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.
Cheung BB, et al.
Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.
Mol Oncol. 2015.
PMID: 25963741
Free PMC article.